Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
- Categories:Press Release
- Author:
- Origin:
- Time of issue:2019-02-19 13:51
- Views:
(Summary description)Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
(Summary description)Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
- Categories:Press Release
- Author:
- Origin:
- Time of issue:2019-02-19 13:51
- Views:
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.
Scan the QR code to read on your phone
Add
Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,
Haidian District, Beijing City, China, 10084
A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123
COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd 苏ICP备19068714号-1 Power by 300.cn Beijing
Follow us